Generic drug stocks

(by market cap)                        
Company name Mkt Cap▼

1. ZTS Zoetis Inc. USA 59.691B; medicine and vaccinations for pets and livestock
2. TEVA Teva Pharmaceuticals Israel 11.532B
3. MYL Mylan, Inc. UK  8.718B
4. 
   
5. SLXP Salix Pharmaceuticals  USA 6.67B
6. MNK Mallinckrodt Ireland 3.91B
7. AKRX Akorn   USA 2.48B
8. IRWD Ironwood Pharmaceuticals   USA 1.75B
9. LGND Ligand Pharmaceuticals USA 1.43B
10. NBIX Neurocrine Biosciences USA 1.18B
11. MNTA Momenta Pharmaceuticals USA 757.54M
12. AVNR Avanir Pharmaceuticals USA 632.74M
13. HITK Hi Tech Pharmacal Co.   USA 593.60M
14. SUPN Supernus Pharmaceuticals   USA 310.65M
15. GALT Galectin Therapeutics USA 286.42M
16. EGRX Eagle Pharmaceuticals   USA 191.29M
17. CPRX Catalyst Pharmaceutical Partners   USA 100.10M
18. CPXX Celator Pharmaceuticals USA 88.49M
19. SPHS Sophiris Bio  USA 36.89M

Acquisitions:

• Sagent Pharmaceuticals (SGNT) was acquired by Nichi-Iko Pharmaceutical of Tokyo for about $736 million. (July 2016)
• Actavis (ACT) acquired Allergan (AGN) and changed its name to Allergan (2015). Generic medications were transferred to Teva Pharmaceuticals (TEVA). In 2019, Allergan (AGN) was acquired by AbbVie (ABBV) 
• Hospira (NYSE:HSP) was the world's largest producer of generic injectable pharmaceuticals. Was acquired by Pfizer (PFE) for $17 billion in September, 2015. (Hospira was Abbott's (ABT) 2004 spinoff.)    August 2019: Pfizer will combine its generic-drug unit, Upjohn, with Mylan. This will create a generics giant with revenues next year of close to $20 billion. The yet-to-be-named firm, of which Pfizer shareholders will own 57%, will market generic versions of once-blockbuster-selling drugs, including the cholesterol drug Lipitor, the erectile dysfunction treatment Viagra, and Lyrica, a nerve pain medication.

finviz charts (ave vol - 30 days, new window): http://finviz.com/screener.ashx?v=211&ta=0&o=-averagevolume&t=ACT,MYL,ZTS,HSP,SLXP,MNK,AKRX,IRWD,LGND,NBIX,MNTA,SGNT,AVNR,HITK,SUPN,GALT,EGRX,CPRX,CPXX,SPHS